A practical reference on BPC-157: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
When HypSys is silenced the production of protease inhibitors induced by wounding is halved compared to wild type plants indicating that both systemin and HypSys are required for a strong defence response against herbivores in tomato. When applied through cut petioles in Petunia, HypSys did not induce the production of protease inhibitors, but instead increased expression of defensin, a gene which produces a protein that inserts into microbial membranes, forming a pore. Defensin expression is also induced by AtPEP1. Tomato plants over-expressing systemin produced more volatile organic compounds (VOCs) than normal plants and parasitoid wasps found them more attractive. Systemin also upregulates the expression of genes involved in the production of biologically active VOCs. Such a response is crucial if antinutritional defences are to be effective, since without predators, developing insects would consume more plant material while completing their development. It is likely that VOC production is upregulated through different pathways, including oxylipin pathway that synthesises jasmonic acid aldehydes and alcohols that function in wound healing. Different AtPeps may allow A. thaliana to distinguish between different pathogens. When inoculated with a fungus, oomycete and a bacterium, the increases in AtPep expression varied depending on the pathogen. A. thaliana overexpressing AtProPep1 was more resistant to the oomycete Phythium irregulare.
They were moved to the Château de Facqueval in Modave, Belgium, where Hahn used the time to work on his memoirs and then, on 3 July, were flown to England. They arrived at Farm Hall, Godmanchester, near Cambridge, on 3 July. While they were there, all their conversations, indoors and out, were covertly recorded with hidden microphones. They were given British newspapers, which Hahn was able to read. He was greatly disturbed by their reports of the Potsdam Conference, where German territory was ceded to Poland and the USSR. In August 1945, the German scientists were informed of the atomic bombing of Hiroshima. Up to this point the scientists, except Harteck, were completely certain that their project was further advanced than any in other countries, and the Alsos Mission's chief scientist, Samuel Goudsmit, did nothing to correct this impression. Now the reason for their incarceration in Farm Hall suddenly became apparent. As they recovered from the shock of the announcement, they began to rationalise what had happened. Hahn noted that he was glad that they had not succeeded, and von Weizsäcker suggested that they should claim that they had not wanted to. They drafted a memorandum on the project, noting that fission was discovered by Hahn and Strassmann. The revelation that Nagasaki had been destroyed by a plutonium bomb came as another shock, as it meant that the Allies had not only been able to conduct uranium enrichment, but had mastered nuclear reactor technology as well. The memorandum became the first draft of a postwar apologia.
The benefits of beak trimming are mainly welfare advantages for birds kept in close confinement, some of which directly relate to increases (or reduced decreases) in production. These include reduced feather pecking and cannibalism, better feathering (though they find it hard to preen with shortened beaks, which means they are not cleaning themselves well), less fearfulness and nervousness, less chronic stress, and decreased mortality.
=== Legal status === On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kapruvia, intended for treatment of moderate-to-severe pruritus associated with chronic kidney disease. The applicant for this medicinal product is Vifor Fresenius Medical Care Renal Pharma France. Difelikefalin was approved for medical use in the European Union in April 2022.
Sources: en.wikipedia.org
=== 17 March === Slovakia decided to provide Ukraine with 13 MiG-29 jets in varying states of readiness. The International Criminal Court issued an arrest warrant against Russian President Vladimir Putin and his Commissioner for Children's Rights Maria Lvova-Belova for allegations of war crimes during the war in Ukraine. Later in March, the Hungarian Prime Minister's chief of staff, Gergely Gulyás, said that Hungary would not arrest Putin if he entered the country, stating that the warrant was inconsistent with Hungarian law.
== Platform technologies == Rosetta Genomics has developed several proprietary technologies that enable the company to work with microRNAs. At the basis of these technologies are proprietary microRNA extraction protocols that include sensitive extraction of microRNAs from most body fluids, including serum, urine, saliva, with virtually no microRNA lost in the extraction process. The company has also developed a microRNA extraction protocol from Formalin Fixed Paraffin Embedded, or FFPE, samples. This allows extraction of microRNAs from samples preserved at room temperature. Once microRNAs are extracted, Rosetta Genomics’ technology is capable of detecting and quantifying the microRNAs using two custom designed platform technologies which utilize Quantitative Real Time PCR (or qRT-PCR) and microarrays. The company's proprietary microarray platform covers approximately 850 human microRNAs, including approximately 180 microRNAs which are Rosetta Genomics’ proprietary microRNAs. The array's high specificity allows discriminating homologous family members.
=== Protecting groups === As a class, esters serve as protecting groups for carboxylic acids. Protecting a carboxylic acid is useful in peptide synthesis, to prevent self-reactions of the bifunctional amino acids. Methyl and ethyl esters are commonly available for many amino acids; the t-butyl ester tends to be more expensive. However, t-butyl esters are particularly useful because, under strongly acidic conditions, the t-butyl esters undergo elimination to give the carboxylic acid and isobutylene, simplifying work-up.
=== Anti-inflammation === Inhibiting inflammatory mediators could help prevent osteoarthritis progression. Cytokines and chemokines are both crucial in stimulating cartilage catabolism and blocking these inflammatory mediators. Studies have shown that treatment with NF-κB pathway inhibitor BAY11-7082 restores IL-1b-inhibited chondrogenesis of cartilage stem cells and in turn postpones progression of OA. Similarly, ample research shows that combined blockade of TNFa and IL-17 with bispecific antibodies reveals an inhibition of both cytokines for reduced cartilage degradation and proinflammatory responses.
Properties also decrease with the age of the fiber. Younger fibers tend to be stronger and more elastic than older ones. Many natural fibers exhibit strain rate sensitivity due to their viscoelastic nature. Bone contains collagen and exhibits strain rate sensitivity in that the stiffness increases with strain rate, also known as strain hardening. Spider silk has hard and elastic regions that together contribute to its strain rate sensitivity, these cause the silk to exhibit strain hardening as well. Properties of natural fibers are also dependent on the moisture content in the fiber.
Sources: en.wikipedia.org
Here cartilage is characterized by a dense extracellular matrix and is rich in proteoglycans (which dispel and reabsorb water to soften impacts) and thin collagen oriented parallel to the joint surface which have excellent shear resistant properties. Osteoarthritis and natural aging both have negative effects on cartilage as a whole as well as the proper function of the materials gradient within. The earliest changes are often in the superficial zone, the softest and most lubricating part of the tissue. Degradation of this layer can put additional stresses on deeper layers which are not designed to support the same deformations. Another common effect of aging is increased crosslinking of collagen fibers. This leads to stiffer cartilage as a whole, which again can lead to early failure as stiffer tissue is more susceptible to fatigue based failure. Aging in calcified regions also generally leads to a larger number of mineral deposits, which has a similarly undesired stiffening effect. Osteoarthritis has more extreme effects and can entirely wear down cartilage, causing direct bone-to-bone contact.
== Overview == Source Filmmaker is a tool for animating, editing and rendering 3D animated videos using assets from most games which use the Source engine, such as sounds, models, and, backdrops. SFM also allows for the creation of still images, art, and posters. SFM contains three different user interfaces and a "work camera" for previewing an active scene. The three interfaces are used for creating clips, controlling animation, and making fine-tuned adjustments, which include:
Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.
=== Legal status === In May 2022, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Upstaza, intended for the treatment of aromatic L‑amino acid decarboxylase (AADC) deficiency. As Upstaza is an advanced therapy medicinal product, the CHMP positive opinion is based on an assessment by the Committee for Advanced Therapies. The applicant for this medicinal product is PTC Therapeutics International Limited. Eladocagene exuparvovec was approved for medical use in the European Union in July 2022. Eladocagene exuparvovec was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) granted the application for eladocagene exuparvovec priority review and orphan drug designations, and a rare pediatric disease priority review voucher. It was approved under the accelerated approval pathway. The FDA granted approval of Kebilidi to PTC Therapeutics.
== National Mass Spectrometry Service == A grant of £670,000 was awarded in 1985 by the then Science and Engineering Research Council (SERC) to establish a national Mass Spectrometry Center at Swansea University to provide an analytical service to British Universities. It was officially opened in April 1987 by Lord Callaghan. In 2002, the center was enlarged and the new laboratories were opened by Lord Morgan. Following successful £3,000,000 contract renewal Edwina Hart, the Minister for Economy, Science and Transport, officially re-opened the EPSRC National Research Facility after refurbishment in 2015.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.